Avantor, Inc. (AVTR) Stock Price & Analysis
Avantor, Inc. (AVTR) rose 2.27% to USD 9.91 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
AVTR last closed at USD 9.69; the session ranged USD 9.52–10.05 on volume of 14,076,966 shares. Market capitalization is $6.77B, with a 52-week range of USD 7.27–15.93 (NYQ). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 9.91 |
|---|---|
| Change | ▲ 2.27% (up) |
| Previous Close | USD 9.69 |
| Open | USD 9.57 |
| Day Range | USD 9.52 – 10.05 |
| 52-Week Range | USD 7.27 – 15.93 |
| Volume | 14,076,966 shares |
| Market Cap | $6.77B |
| Exchange | NYQ |
Technical Analysis (AVTR)
Nexqual's technical model rates AVTR "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.13 (overbought) |
| vs SMA50 | Above (USD 8.27) |
| MACD | 0.41 (positive) |
Analyst Ratings (AVTR)
Wall Street analysts rate AVTR "Hold" based on 15 analysts, with a mean price target of USD 9.67 (range USD 7–19), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 9.67 |
| High Target | USD 19 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 3 / 10 / 3 |
Earnings (AVTR)
| Next Earnings Date | 2026-04-29 |
|---|---|
| EPS Estimate | USD 0.19 |
| Revenue Estimate | $1.61B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.17 vs est 0.16 ▲ beat |
| 2025-12-31 | USD 0.22 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.22 vs est 0.23 ▼ miss |
| 2025-06-30 | USD 0.24 vs est 0.25 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (AVTR)
| Total Revenue | $6.55B |
|---|---|
| Revenue Growth (YoY) | +0.00% |
| Gross Margin | +32.13% |
| Operating Margin | +6.26% |
| Profit Margin | -8.42% |
| ROE | -9.44% |
| Debt / Equity | 68.29 |
| Current Ratio | 1.76 |
| Total Cash | $279.30M |
| Total Debt | $3.82B |
| Free Cash Flow | $489.36M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (AVTR)
Nexqual rates Avantor, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 6% |
| Balance Sheet | Solid — $279M cash vs $3.82B debt |
| Cash Flow | Solid — FCF $489M, 7% margin |
| Efficiency | Critical — ROE -9%, ROA 2.8% |
Ownership (AVTR)
| Insider Ownership | +1.49% |
|---|---|
| Institutional Ownership | +101.56% |
| Shares Outstanding | 682.76M |
| Float | 664.29M |
| Short % of Float | +6.87% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (AVTR)
Avantor, Inc. is led by Emmanuel Ligner (age 54), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.
| President, CEO & Director | Emmanuel Ligner (age 54) |
|---|---|
| President of Laboratory Solutions | Corey D. Walker (age 47) |
| Executive Vice President of Bioscience Production | Benoit Gourdier (age 58) |
| Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Steven W. Eck (age 49) |
| Executive VP & COO | Mary Blenn |
Major Backers & Investors (AVTR)
Notable institutional backers of Avantor, Inc. include Dodge & Cox Inc., Wellington Management, Greenhaven Associates, Inc., according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 29.63% |
| Wellington Management | 3.55% |
| Greenhaven Associates, Inc. | 3.31% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 3.27% |
| Engine Capital Management, LP | 2.9% |
| Touchstone Fd.s Group TRT-Touchstone Fd.s Group TRT-Touchstone Mid Cap | 1.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.13% |
| BlackRock | 12.99% |
| State Street | 3.03% |
| Dimensional Fund Advisors | 2.47% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
From Avantor, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
- The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.
- It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies.
- In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELAN | Elanco Animal Health Incorporat | USD 24.5 | ▲ 3.68% |
| AXTA | Axalta Coating Systems Ltd. | USD 32.85 | ▲ 2.08% |
| IQV | IQVIA Holdings, Inc. | USD 186.25 | ▲ 1.53% |
| NVST | Envista Holdings Corporation | USD 24.59 | ▲ 6.45% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.